Vistagen Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Vistagen Therapeutics Inc in the first quarter 2026?
Vistagen Therapeutics Inc recorded a cumulative net loss of $-68 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -137.49%.

Within the Major Pharmaceutical Preparations industry 281 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2026 from 3541 to 3598.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Equity Change	-56.87 %	-49.54 %	-38.41 %	-28.65 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-68	-70	-67	-62	-56
Return On Equity (TTM)	-137.49 %	-121.71 %	-101.63 %	-80.88 %	-66.72 %
VTGN's Total Ranking	# 3598	# 3541	# 3183	# 2923	# 2702
Equity (TTM) in Millions	24	36	70	66	57
Seq. Equity Change	-31.08 %	-49.54 %	6.11 %	16.87 %	-19.36 %
Seq. Net Income Change	-	-	-	-	-

Back to VTGN Management Effectiveness >> VTGN's 5 Years Annual ROE >> Compare VTGN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 282
Sector	# 605
Overall	# 3598

Return On Equity Statistics
High	Average	Low
-44.38 %	-406.8 %	-3772.88 %
(Dec 31 2024)		(Jun 30 2017)

News about Vistagen Therapeutics Inc Return on Equity ROE

Vistagen Launches Hopeful New Phase 3 Trial for Fasedienol A Game Changer in the Battle Against Social Anxiety D...

In a significant advancement for mental health treatment, Vistagen Therapeutics, a neuroscience-focused biopharmaceutical company based in South San Francisco, has announced the commencement of its PALISADE-4 Phase 3 clinical trial for fasedienol. This investigational neuroactive pharmaceutical, delivered via nasal spray, aims to provide a new therapeutic option for individuals suffering from Social Anxiety Disorder (SAD), a condition affecting millions worldwide. Understanding Social Anxiety DisorderSocial Anxiety Disorder, characterized by an intense fear of social interactions and performance situations, impacts the lives of countless individuals. Patients often experience overwhelming anxiety and self-consciousness, which can lead to avoidance behaviors and significantly impair daily functioning. Despite the availability of traditional treatments such as selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT), a notable number of patients remain inadequately treated, underscoring the pressing need for innovative therapeutic approaches.

VTGN Annual Return On Equity	(Mar 31 2026) 2026	(Mar 31 2025) 2025	(Mar 31 2024) 2024	(Mar 31 2023) 2023	(Mar 31 2022) 2022
Total Equity in Millions	36	70	114	12	65
Y / Y Equity Change	-49.54 %	-38.41 %	846.08 %	-81.33 %	-29.64 %
Net Income in Millions	-70	-51	-29	-59	-48
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-196.19 %	-73.05 %	-25.69 %	-490.46 %	-73.8 %

Back to VTGN Management Effectiveness >> VTGN's 5 Years Annual ROE >> Compare VTGN ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VTGN's' Return on Equity at Yahoo Finance
VTGN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VTGN's Competitors
Subscribers only: Roe for Vistagen Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for VTGN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T22:48:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.